This article first appeared on GuruFocus .
-
Revenue Growth:Increased by 7.6% in constant currencies and 4.7% in reported currencies, reaching slightly more than 3.5 billion.
-
EBITDA Margin:Improved by 170 basis points to 29.7%.
-
Order Intake:Grew faster than sales, with a 12-month rolling book-to-bill ratio consistently above one.
-
Bioprocess Solutions Revenue Growth:9.5% in constant currency.
-
Lab Products and Services Revenue Growth:Essentially flat at 0.2% in constant currencies.
-
Underlying EBITDA:Increased by 11.2% to 1.052 billion.
-
Net Profit Growth:Underlying net profit increased by 18%, reported net profit by 84%.
-
Operating Cash Flow:837 million, below the prior year level of 976 million.
-
Free Cash Flow:390 million.
-
CapEx Ratio:12.5%, in line with guidance.
-
Equity Ratio:39.8%.
-
Net Debt to EBITDA Ratio:Improved from 3.96 times to 3.55 times.
-
Sartorius Stedim Biotech Revenue Growth:9.6% in constant currencies, reaching nearly 3 billion.
-
Sartorius Stedim Biotech EBITDA Margin:Improved to 30.8%, an increase of 2.8 percentage points.
-
Sartorius Stedim Biotech Net Profit Growth:Underlying net profit increased by 26.7% to 428 million.
-
Sartorius Stedim Biotech Free Cash Flow:295 million.
-
Sartorius Stedim Biotech Equity Ratio:Improved to 51.7%.
-
Sartorius Stedim Biotech Net Debt to EBITDA Ratio:Improved to 2.38 by the end of 2025.
Release Date: February 03, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Sartorius Stedim Biotech SA ( SDMHF ) achieved considerable profitable growth in 2025, driven by improving demand trends, particularly for consumables.
-
The company delivered results slightly ahead of its upgraded full-year 2025 sales guidance, with profitability landing in the upper half of the initial guidance.
-
Strong double-digit growth in recurring revenue more than offset continued softness in equipment, which stabilized over the year.
-
The company made tangible progress in innovation and partnerships, launching several new solutions across both divisions, including sustainable product designs and advanced bioanalytical tools.
-
Sartorius Stedim Biotech SA ( SDMHF ) further reduced its leverage ratio, underscoring its commitment to financial discipline and a strong balance sheet.
Negative Points
-
The equipment business remained soft throughout 2025, although it showed signs of stabilization in the second half of the year.
-
The company faced headwinds from a weaker US dollar, which negatively impacted reported sales growth by almost 300 basis points.
-
Operating cash flow decreased compared to the previous year, influenced by significant one-off inventory reduction measures in 2024.
-
The lab products and services division experienced a decline in margin due to an unfavorable product mix and FX impacts.
-
The company set a broad guidance range for 2026 due to continued macroeconomic and industry-specific volatility, reflecting uncertainty in market conditions.
Q & A Highlights
Q: What does your guidance assume in terms of US onshoring buildouts in 2026, and what could drive upside to these expectations? A: Michael Grosse, CEO, explained that while there are many plans for US onshoring, the impact from large reshoring activities is not expected to contribute to revenue in 2026. This is anticipated to have a larger impact in 2027 and beyond. The company is closely connected with customers to support their plans.
Q: How did equipment orders for Bioprocess Solutions (BPS) and Lab Products and Services (LPS) trend for Q4, and are there signs of recovery? A: Florian Funck, CFO, noted that while detailed information isn't provided, H2 sales and order intake were stronger than H1, indicating a positive trend and supporting a cautiously optimistic outlook for 2026.
Q: Can you elaborate on the stabilization of equipment revenues and when equipment could return to normal levels? A: Rene Faber, Head of Bioprocess Solutions Division, stated that H2 2025 showed stronger equipment revenues compared to H1, confirming stabilization. Positive discussions with customers and a healthy order book support a cautiously optimistic outlook for 2026, though full recovery may take more time.
Q: How does your 2026 guidance reflect potential market conditions and margin expectations? A: Florian Funck, CFO, explained that the guidance accounts for a 50 basis point impact from tariffs and potential FX headwinds. The margin improvement is expected to be driven by operational leverage, with a cautious approach due to macroeconomic uncertainties.
Q: What are the potential risks to market share in the consumables segment, and how do you see growth in this area? A: Rene Faber highlighted that consumables represent a significant portion of revenues, driven by commercial manufacturing volumes. The company has a strong track record of gaining market share and expects continued healthy growth in consumables, supported by customer relationships and product validation.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
